VENUS REMEDIES LIMITED Valuation
VENUSREM · Healthcare · Current price ₹1,602.9
Is VENUS REMEDIES LIMITED undervalued?
DocStoX estimates the fair value of VENUS REMEDIES LIMITED at ₹1,101 per share, versus the current market price of ₹1,603. That puts the stock about -31.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹533), Relative P/E (₹2,332), Graham floor (₹927). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹533 (bear) to ₹1,101 (base) to ₹2,332 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
VENUS REMEDIES LIMITED trades at a P/E of 20.8x and a P/B of 3.5x, with a dividend yield of 0.6%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on VENUS REMEDIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.